ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
67 announcements with these filters
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹629.6 Cr (+4.7% YoY) and net profit of ₹165.9 Cr (+28.3% YoY) for Q1 FY27.
Dr. Lal Path Labs has granted 119,300 stock options to eligible employees under its 2025 Restricted Stock Unit Plan.
Dr. Lal Path Labs' subsidiary will acquire an 80% stake in Sunshine Healthcare Limited, Ghana. The transaction is valued at ₹38.0 Crore.
Dr. Lal Path Labs' subsidiary, Dr. Lal Ventures, is acquiring a 30% stake in Neuome Technologies for ₹3.5 Crore. This provides access to innovative bio-banking solutions.
Dr. Lal Path Labs declared an interim dividend of ₹5 per equity share. The record date for payment is July 30, 2026.
Dr. Lal PathLabs reported strong Q1 FY27 results with 19.1% revenue growth and 27.2% PAT growth. Strategy remains focused on scientific leadership, patient experience, and operational excellence.
Dr Lal PathLabs reported Q1 FY27 revenue of ₹798 Crore, growing 19.1% YoY. PAT for the quarter increased to ₹170 Crore.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹797.7 Cr (+19.1% YoY) and net profit of ₹170.5 Cr (+27.2% YoY) for Q1 FY27.
Dr. Lal PathLabs Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details the distribution of equity shares across various investor categories.
Dr. Lal Path Labs received a favorable Income Tax appellate order for FY 2021-22. The 32.66 Crore ESOP expense deduction was successfully allowed.
Dr. Lal PathLabs received a favorable appellate order from the Income Tax Department. The order allows a tax deduction of Rs.32.66 Crore regarding ESOP expenses.
Dr. Lal PathLabs' Board will meet on July 24, 2026. The meeting agenda includes approving quarterly results and considering an interim dividend.
Dr. Lal PathLabs has sent letters to shareholders without registered emails. The communication provides a web-link to access the Annual Report for FY 2025-26.
Dr. Lal PathLabs reported FY2025-26 revenue of ₹2,762.9 Crore and PAT of ₹509.8 Crore. The annual report highlights 312 labs, 3.22 MW solar capacity and CSR spend of ₹102.2 Crore.
Dr. Lal PathLabs submitted its Business Responsibility & Sustainability Report for FY 2025‑26 to the NSE. The filing details its ESG initiatives and employee statistics.
Dr. Lal PathLabs Ltd has issued a notice for its 32nd Annual General Meeting on 25 July 2026. Shareholders are invited to attend via video conferencing.
Dr. Lal PathLabs scheduled a Board meeting on 24‑Jul‑2026 to approve its unaudited QJune‑30‑2026 results. Trading window will be closed from 1 to 26 July 2026.
Dr. Lal PathLabs incorporated a new wholly owned subsidiary in Dubai for ₹49.75 Crore. The entity will focus on international diagnostic service expansions and strategic investments.
Dr. Lal PathLabs Ltd incorporated a wholly owned subsidiary in Dubai named DR LAL PATHLABS FZCO. This subsidiary will focus on diagnostics and allied activities, including potential acquisitions and joint ventures.
Dr. Lal PathLabs reported strong Q4 FY26 results with 16.6% revenue growth. Focus remains on expansion through 1,100+ new collection centers and high-end diagnostic branding.
Dr. Lal Path Labs Ltd. has completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) for ₹20 Crore. Following the transaction, SDCPL has become a wholly owned subsidiary of the company. This acquisition strengthens the company's diagnostic footprint.
Dr. Lal PathLabs Ltd. has successfully completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 01, 2026. SDCPL is now a wholly-owned subsidiary of the company, following the terms of the Share Purchase Agreement signed on April 30, 2026.
Dr. Lal PathLabs announced the re-appointment of (Hony) Brig. Dr. Arvind Lal as Executive Chairman for five years from April 2027. The board also designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel and re-appointed Ernst & Young LLP as internal auditors for FY 2026-27.
Dr. Lal Path Labs Ltd. allotted 82,750 equity shares on April 30, 2026, following the exercise of options under its Employee Stock Option Plan 2022. This allotment increases the company's paid-up share capital to 167,637,770 shares.
Dr. Lal Path Labs Ltd. recommended a final dividend of ₹4 per equity share (40% on face value) for FY 2025-26. The record date for payment is June 26, 2026, with the final payout expected by August 24, 2026, following shareholder approval at the AGM on July 25, 2026.
Dr. Lal Path Labs Ltd. will acquire a 100% stake in Mumbai-based Shahbazkers Diagnostic Centre Private Limited for ₹20 Crore. The cash transaction is expected to conclude by May 31, 2026. This acquisition aims to strengthen the company’s diagnostic service presence in Mumbai, Maharashtra.
Dr. Lal Path Labs Ltd. is incorporating a new wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO. The subsidiary will focus on diagnostic services and allied activities, including potential acquisitions and joint ventures in the region. The investment will be made at face value subject to regulatory approvals.
Dr. Lal PathLabs reported strong Q4 FY26 revenue growth of 16.6% YoY, driven by volume momentum. The company is focusing on digital transformation and expanding into Tier 3+ markets.
Dr. Lal PathLabs delivered steady growth in Q4 FY26, with revenue rising 16.6% YoY to ₹703 cr. Performance was driven by high sample volumes and expansion into Tier 3+ markets.
Dr. Lal PathLabs Limited reported Q4 FY26 revenue of ₹703 Crore, marking 16.6% year-on-year growth. EBITDA for the quarter rose 10.5% to ₹187 Crore with a 26.6% margin, while PAT stood at ₹132 Crore. The company also declared a final dividend of 40% (Rs. 4 per share).